Neurocrine Bioscience Stock
€110.10
Your prediction
Neurocrine Bioscience Stock
Pros and Cons of Neurocrine Bioscience in the next few years
Pros
Cons
Performance of Neurocrine Bioscience vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Neurocrine Bioscience | 0.990% | -8.020% | 0.228% | -17.373% | -17.156% | 7.709% | 12.715% |
| Ironwood Pharmaceuticals | -0.740% | -4.255% | 7.143% | -88.158% | -83.929% | -94.144% | -92.012% |
| Novocure Ltd | -0.890% | 1.496% | -35.311% | -45.124% | -66.456% | -86.857% | -85.307% |
| Iovance Biotherapeutics Inc. | -5.540% | -5.294% | 49.149% | -68.784% | -68.006% | -81.919% | -91.584% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Neurocrine Biosciences (NASDAQ: NBIX), a company operating in the Biotechnology & Medical Research industry, showcases an interesting financial outlook. The company's financials indicate a growing revenue base and a healthy mix of both current and non-current assets. However, there are also aspects where the company could potentially face challenges, warranting a deeper analysis of its financial standing.
Growing Revenue: Neurocrine has consistently increased its revenue over the past three years, with total revenues of $1.05 billion in 2020, $1.13 billion in 2021, and $1.49 billion in 2022. This reflects a strong demand for the company's products and services.
Increasing Gross Profit: The gross profit has seen a continuous upward trend with $1.04 billion in 2020, $1.12 billion in 2021, and $1.47 billion in 2022. This suggests that the company is efficiently managing its cost of revenue, enabling higher profitability.
Comments
News
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Neurocrine Biosciences (NASDAQ:NBIX), a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market